Delisting risk
NRSN · NASDAQ · Biotechnology

NeuroSense Therapeutics (NRSN)

Develops PrimeC, a fixed-dose combination therapy for ALS.

$0.4240
Pre-market−0.00 (−0.21%)
At close$0.4249(+1.14%)

Something off on this page? Send us feedback.

EPSReportedEstimate

Mar '24Apr '24Sep '24Dec '24Apr '25May '25Dec '25Apr '26
Reported−$0.16−$0.16−$0.02−$0.11−$0.06−$0.11−$0.11−$0.24
Estimate−$0.20−$0.20−$0.20−$0.16−$0.11−$0.10−$0.07
Surprise+20.0%+20.0%+90.0%+31.3%+45.5%−4.8%−231.9%

RevenueReportedEstimate

Mar '24Apr '24Sep '24Dec '24Apr '25May '25Dec '25Apr '26
Reported
Estimate
Surprise

History

DateEstimateReportedSurprise
Jun 2026−$0.07
Jun 2026−$0.08
Apr 2026−$0.07−$0.24−231.9%
Dec 2025−$0.11
May 2025−$0.10−$0.11−4.8%
Apr 2025−$0.11−$0.06+45.5%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Dec 2024
Sep 2024
Apr 2024
Mar 2024
Nov 2023
Aug 2023
Jun 2023
Mar 2023
Dec 2022
Aug 2022
May 2022
Apr 2022
Dec 2021
Sep 2021
Jun 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Jun 30, 2026−$0.07$514.1K
Jun 22, 2026−$0.08$514.1K
Apr 6, 2026−$0.07−$0.24−231.9%−0.3%
Dec 17, 2025−$0.11−1.4%
May 28, 2025−$0.10−$0.11−4.8%−5.1%
Apr 7, 2025−$0.11−$0.06+45.5%−2.3%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Dec 18, 2024
Sep 30, 2024
Apr 5, 2024
Mar 22, 2024
Nov 28, 2023
Aug 16, 2023
Jun 1, 2023
Mar 22, 2023
Dec 1, 2022
Aug 31, 2022
May 31, 2022
Apr 14, 2022
Dec 10, 2021
Sep 21, 2021
Jun 30, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020